Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 29:11:622468.
doi: 10.3389/fimmu.2020.622468. eCollection 2020.

The Role of the Adipokine Leptin in Immune Cell Function in Health and Disease

Affiliations
Review

The Role of the Adipokine Leptin in Immune Cell Function in Health and Disease

Kaitlin Kiernan et al. Front Immunol. .

Abstract

Leptin is a critical mediator of the immune response to changes in overall nutrition. Leptin is produced by adipocytes in proportion to adipose tissue mass and is therefore increased in obesity. Despite having a well-described role in regulating systemic metabolism and appetite, leptin displays pleiotropic actions, and it is now clear that leptin has a key role in influencing immune cell function. Indeed, many immune cells have been shown to respond to leptin directly via the leptin receptor, resulting in a largely pro-inflammatory phenotype. Understanding the role of adipose-tissue derived mediators in inflammation is critical to determining the pathophysiology of multiple obesity-associated diseases, such as type 2 diabetes, autoimmune disease, and infection. This review, therefore, focuses on the latest data regarding the role of leptin in modulating inflammation.

Keywords: adaptive immunity; adipose tissue; inflammation; leptin; obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Leptin receptor isoforms and intracellular signaling. (A) Leptin receptor is composed of an extracellular domain, a transmembrane domain, and a cytoplasmic domain. All variants of the leptin receptor include the extracellular domain. The extracellular domain is composed of several protein motifs: the N terminal domain (NTD), two cytokine receptor homology (CRH) domains that make up the leptin binding site, an immunoglobulin-like domain (IGD), and two fibronectin type 3 (FN III) domains. The cytoplasmic domain of leptin receptor varies between isoforms. LRb, the long form receptor, includes two box domains and several tyrosine residues important for leptin receptor signaling. The other leptin receptor variants are labeled LRa, LRc, LRd, LRf and they all have the complete extracellular binding domain, but their intracellular tails differ; however, they all contain the two box domains. There is also a soluble form of leptin receptor in both humans and mice called LRe. In mice, LRe is directly secreted, while in humans, LRe is generated by ectodomain shedding (metalloproteases cut the receptor off the surface). (B) Leptin receptor isoforms are generated by alternative splicing or processing at the cell membrane. The long form of leptin receptor, also known as LRb, is the only known receptor variant that is capable of signaling through the JAK-STAT pathway. LRb has a long intracellular tail that includes several tyrosine residues that are phosphorylated for signal transduction by JAK2. LRb signaling primarily occurs through the JAK2/STAT3 pathway, with STAT3 translocating to the nucleus to modify gene expression. LRb also signals through the PI3K/Akt pathway and the MAPK pathway. These pathways in immune cells have been shown to lead to metabolic and functional changes, which could account for the pleiotropic effects of leptin on different immune cell types (–58).

Similar articles

  • Leptin and Leptin Signaling in Multiple Sclerosis: A Narrative Review.
    Flores-Cordero JA, Aranaz-Murillo A, Vilariño-García T, Pérez-Pérez A, Izquierdo G, Flores-Campos R, Hontecillas-Prieto L, García-Domínguez DJ, Sánchez-Margalet V. Flores-Cordero JA, et al. Neuromolecular Med. 2025 Feb 28;27(1):19. doi: 10.1007/s12017-025-08842-4. Neuromolecular Med. 2025. PMID: 40019662 Free PMC article. Review.
  • An update on leptin as immunomodulator.
    Conde J, Scotece M, Abella V, López V, Pino J, Gómez-Reino JJ, Gualillo O. Conde J, et al. Expert Rev Clin Immunol. 2014 Sep;10(9):1165-70. doi: 10.1586/1744666X.2014.942289. Epub 2014 Aug 7. Expert Rev Clin Immunol. 2014. PMID: 25098336 Review.
  • Adipose tissue, adipokines, and inflammation.
    Fantuzzi G. Fantuzzi G. J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920. doi: 10.1016/j.jaci.2005.02.023. J Allergy Clin Immunol. 2005. PMID: 15867843 Review.
  • Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Bastard JP, et al. Eur Cytokine Netw. 2006 Mar;17(1):4-12. Eur Cytokine Netw. 2006. PMID: 16613757 Review.
  • Role of leptin in the activation of immune cells.
    Fernández-Riejos P, Najib S, Santos-Alvarez J, Martín-Romero C, Pérez-Pérez A, González-Yanes C, Sánchez-Margalet V. Fernández-Riejos P, et al. Mediators Inflamm. 2010;2010:568343. doi: 10.1155/2010/568343. Epub 2010 Mar 23. Mediators Inflamm. 2010. PMID: 20368778 Free PMC article. Review.

Cited by

References

    1. Kopelman P. Health risks associated with overweight and obesity. Obesity Rev (2007) 8(s1):13–7. 10.1111/j.1467-789X.2007.00311.x - DOI - PubMed
    1. Haslam DW, James WP. Obesity. Lancet (2005) 366(9492):1197–209. 10.1016/S0140-6736(05)67483-1 - DOI - PubMed
    1. Alwarawrah Y, Kiernan K, MacIver NJ. Changes in Nutritional Status Impact Immune Cell Metabolism andFunction. Front Immunol (2018)9:1055–69. 10.3389/fimmu.2018.01055 - DOI - PMC - PubMed
    1. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest (1995) 95(5):2111–9. 10.1172/JCI117899 - DOI - PMC - PubMed
    1. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest (1995) 95(5):2409–15. 10.1172/JCI117936 - DOI - PMC - PubMed

Publication types